background: we conducted a retrospective analysis to evaluate the impact of omission of supraclavicular radiotherapy on supraclavicular failure rate and treatment outcomes in n1 breast cancer patients with evaluation of prognostic factors that affected supraclavicular recurrence free survival. methods: this study analyzed the medical records of 109 patients with n1 breast cancer. all patients u...

PURPOSE/OBJECTIVES To provide an overview of the risks for and occurrence of chemotherapy-induced neutropenia in patients with cancer and its optimal prophylactic management with recombinant human granulocyte-colony-stimulating factor (G-CSF). DATA SOURCES Original research, review articles, conference presentations, and published guidelines. DATA SYNTHESIS Chemotherapy-induced neutropenia ...

Despite improvements in adjuvant chemotherapy regimens in breast cancer, personalised use of specific cytotoxic regimens remains a clinical challenge. Defining the correct therapeutic strategy for individual patients with breast cancer based on the genomic and transcriptomic characteristics of the tumour and the patient remains an area of unmet clinical need. Despite the promise of microarray-b...

Continuing Avastin beyond the time when advanced crc gets worse helps patients, according to new study reports. Patients who continued to receive avastin with a new chemotherapy regimen after their cancer first progressed lived almost 12 months longer than patients who got more chemo but stopped avastin. Both groups did better than those who had no further treatment at all. The BRITE (Bevacizum...

The triplet combination of encorafenib, cetuximab, plus binimetinib (BEACON regimen) showed survival benefit and a higher response over standard chemotherapy in pretreated patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) the BEACON CRC study. regimen as well encorafenib cetuximab are approved previously treated mCRC Japan, but limited number Japanese regimen. An expanded acce...

A case of hyperammonaemic encephalopathy that developed during the administration of a widely used chemotherapy regimen is reported in a 51-year-old man. 5-Fluorouracil was considered to be the causative agent. Although encephalopathy is a rare toxic effect of 5-fluorouracil, this case illustrates a serious and potentially life-threatening complication during a chemotherapy regimen using 5-fluo...

The role of second-line and salvage chemotherapy in malignant pleural mesothelioma treatment is not yet established. We report a case of relapsed malignant pleural mesothelioma in which the patient failed to respond to pemetrexed-based chemotherapy but was successfully treated with gemcitabine and vinorelbine. The patient underwent a left extrapleural pneumonectomy. Three years later she develo...

Children with acute lymphoblastic leukemia (ALL) who have completed 2.5 to 3 years of initial chemotherapy have an off-therapy relapse rate of approximately 20%. In an attempt to improve the survival of children with a late bone marrow (BM) relapse (ie, occurring greater than 6 months after cessation of primary therapy), the Pediatric Oncology Group designed a randomized study to compare the ef...

The impact of combining epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) remains controversial. Therefore, randomized trials that compared this combined regimen with chemotherapy or EGFR-TKIs monotherapy were included for this meta-analysis. We used published hazard ratios...

Adrenocortical cancer is an orphan tumor with poor prognosis. The combination of EDP chemotherapy regimen and mitotane the standard for first‑line therapy. But there are no effective options second consequent lines second‑line therapy gemcitabine, capecitabine mitotane, which provides objective response in 4–7 % patients. Achievement therapeutic concentration most important predictive factor ef...